| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/FON.14.84 |
| P698 | PubMed publication ID | 25052755 |
| P50 | author | Miles C Andrews | Q55294752 |
| Katherine Woods | Q58086041 | ||
| Jonathan Cebon | Q64683306 | ||
| Andreas Behren | Q39062050 | ||
| P2093 | author name string | Jonathan Cebon | |
| Katherine Woods | |||
| Andreas Behren | |||
| Miles C Andrews | |||
| P2860 | cites work | Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. | Q50954469 |
| Predicting clinical outcome through molecular profiling in stage III melanoma. | Q51871342 | ||
| Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients. | Q53241159 | ||
| Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects. | Q54473462 | ||
| High response rate after intratumoral treatment with interleukin-2 | Q56986750 | ||
| B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion | Q22010866 | ||
| A yeast two-hybrid system using Sp17 identified Ropporin as a novel cancer-testis antigen in hematologic malignancies | Q24307899 | ||
| A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma | Q24319940 | ||
| The response of autologous T cells to a human melanoma is dominated by mutated neoantigens | Q24535034 | ||
| Cancer immunotherapy: moving beyond current vaccines | Q24548229 | ||
| Human neoplasms elicit multiple specific immune responses in the autologous host | Q24564371 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1 | Q24633445 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| PD-L2 is a second ligand for PD-1 and inhibits T cell activation | Q28202471 | ||
| Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase | Q28204166 | ||
| Adoptive immunotherapy for cancer: harnessing the T cell response | Q28262548 | ||
| Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression | Q28269191 | ||
| The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity | Q28281686 | ||
| Sequence analysis of the MAGE gene family encoding human tumor-rejection antigens | Q28295548 | ||
| Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase | Q28730430 | ||
| Gene Expression Profiling of Primary Cutaneous Melanoma and Clinical Outcome | Q29011337 | ||
| Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 | ||
| Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 | Q29616128 | ||
| Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape | Q29620881 | ||
| Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma | Q30423599 | ||
| Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination | Q30491014 | ||
| Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice | Q33312280 | ||
| Genome-wide analysis of cancer/testis gene expression | Q33393581 | ||
| Therapeutic vaccines in solid tumours: can they be harmful? | Q33455110 | ||
| Self-antigen presentation by thymic stromal cells: a subtle division of labor | Q33860558 | ||
| BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice | Q33996674 | ||
| Immunotherapy of melanoma: targeting defined antigens | Q34037423 | ||
| Cancer stem cells versus phenotype-switching in melanoma | Q34132378 | ||
| CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients | Q34154427 | ||
| Directed phenotype switching as an effective antimelanoma strategy. | Q34352683 | ||
| A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. | Q34461203 | ||
| The enemy within: keeping self-reactive T cells at bay in the periphery | Q34573771 | ||
| LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems | Q34700552 | ||
| Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma | Q34743450 | ||
| In vivo switching of human melanoma cells between proliferative and invasive states | Q34745037 | ||
| Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer | Q34849409 | ||
| Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity | Q35870655 | ||
| Trial Watch: Adoptive cell transfer immunotherapy | Q36057432 | ||
| Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma | Q36194822 | ||
| PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint | Q36194853 | ||
| Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma | Q36353361 | ||
| Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma | Q36371068 | ||
| Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. | Q36439488 | ||
| Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. | Q36471827 | ||
| Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy | Q36637039 | ||
| Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma | Q36908347 | ||
| Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. | Q36973676 | ||
| Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans | Q36986730 | ||
| A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors | Q37007590 | ||
| Trial watch: Oncolytic viruses for cancer therapy | Q37028023 | ||
| Immune surveillance against a solid tumor fails because of immunological ignorance | Q37178041 | ||
| Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma | Q37375286 | ||
| Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis | Q37526231 | ||
| Cancer/testis (CT) antigens: potential targets for immunotherapy | Q37589698 | ||
| Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma | Q37727061 | ||
| Overcoming immunological tolerance to melanoma: Targeting CTLA-4. | Q37756210 | ||
| Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1. | Q37762274 | ||
| Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes | Q37851050 | ||
| Melanoma vaccines: developments over the past 10 years. | Q37892595 | ||
| Review and cross-validation of gene expression signatures and melanoma prognosis. | Q37940188 | ||
| Oncolytic virotherapy | Q38025263 | ||
| Adoptive immunotherapy of advanced melanoma | Q38032141 | ||
| Adoptive T-cell transfer in melanoma | Q38068968 | ||
| Resistance to BRAF-targeted therapy in melanoma | Q38071800 | ||
| Chemoimmunotherapy: reengineering tumor immunity | Q38079749 | ||
| From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer | Q38098366 | ||
| Targeting MAPK pathway in melanoma therapy | Q38098888 | ||
| BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. | Q39212469 | ||
| MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. | Q39417513 | ||
| BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency | Q39649761 | ||
| Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function | Q39692699 | ||
| The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations | Q39803993 | ||
| Getting personal with neoantigen-based therapeutic cancer vaccines | Q39945813 | ||
| CpG methylation of the IFNG gene as a mechanism to induce immunosuppression [correction of immunosupression] in tumor-infiltrating lymphocytes | Q39953219 | ||
| Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells | Q40010148 | ||
| Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1. | Q40284441 | ||
| Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance | Q40422790 | ||
| Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside | Q40494120 | ||
| NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors | Q40564045 | ||
| Cancer immunotherapy turns viral | Q40725853 | ||
| BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer | Q42417533 | ||
| Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells | Q42581359 | ||
| Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature | Q42804978 | ||
| Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. | Q42830166 | ||
| Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma | Q42874163 | ||
| Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase | Q45760359 | ||
| Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy | Q45871925 | ||
| Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial | Q46066846 | ||
| BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. | Q46460163 | ||
| Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation | Q46897065 | ||
| Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides | Q48614800 | ||
| Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. | Q50954464 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1457-1468 | |
| P577 | publication date | 2014-06-01 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | Evolving role of tumor antigens for future melanoma therapies | |
| P478 | volume | 10 |
| Q36629345 | An inducible transgenic mouse breast cancer model for the analysis of tumor antigen specific CD8+ T-cell responses |
| Q51092888 | Immunotherapy in NSCLC: A Promising and Revolutionary Weapon. |
| Q37059928 | Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy |
| Q38547265 | Proteogenomics meets cancer immunology: mass spectrometric discovery and analysis of neoantigens |
| Q92943708 | Self-Assembled, Adjuvant/Antigen-Based Nanovaccine Mediates Anti-Tumor Immune Response against Melanoma Tumor |
Search more.